Substance P

International Journal of Biochemistry and Cell Biology

Volumn 33, Issue 6, 2001, Pages 555-576

  Harrison, Selena ^a   Geppetti, Pierangelo ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE RECEPTOR STIMULATING AGENT; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR AGONIST; SUBSTANCE P; SUBSTANCE P ANTAGONIST; TACHYKININ RECEPTOR; TACHYKININ RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ASTHMA; CHRONIC BRONCHITIS; CHRONIC INFLAMMATION; CYSTITIS; DEPRESSION; DISEASE ASSOCIATION; DISEASE MODEL; ENTERITIS; HORMONE METABOLISM; HORMONE SYNTHESIS; HUMAN; INFLAMMATORY DISEASE; MIGRAINE; NERVE ENDING; NEUROGENIC INFLAMMATION; NEUROTRANSMISSION; NONHUMAN; PAIN; REVIEW; SEIZURE; SUBSTANCE P AGONIST; TISSUE REACTION; TRANSGENIC MOUSE; VOMITING;

AMINO ACID SEQUENCE; ANIMALS; HUMANS; MICE; MOLECULAR SEQUENCE DATA; RECEPTORS, NEUROKININ-1; RECEPTORS, TACHYKININ; SUBSTANCE P;

EMESIS; MUS MUSCULUS;

EID: 0034982870     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-2725(01)00031-0     Document Type: Review

References (253)

1. An unidentified depressor substance in certain tissue extracts
2. Depressor substances in extracts of intestine
3. Zur frage der zentralen ubertragung afferenter impulse. III. Mitteilung. Das vorkommen und die bedeutung der substanz P. in den dorsalen wurzein des ruckenmarks
4. Release of substance P-like immunoreactivity from isolated spinal cord of newborn rat
5. Neurotransmitter functions of mammalian tachykinins
6. Amino-acid sequence of substance P
7. Amphibian skin peptides in mammals - Looking ahead
8. Conformational analysis of the tachykinins in solution: Substance P and physalaemin
9. Analysis of tachykinin binding site interactions using constrained analogues of tachykinins
10. Receptors and antagonists for substance P and related peptides
11. Structure, expression, and some regulatory mechanisms of the rat preprotachykinin gene encoding substance P, neurokinin A, neuropeptide K, and neuropeptide gamma
12. Substance P precursor and kininogen: Their structures, gene organizations, and regulation
13. Structure and gene organization of bovine neuromedin K precursor
14. Central and peripheral expression of neurokinin-1 and neurokinin-3 receptor and substance P-encoding messenger RNAs: Peripheral regulation during formalin-induced inflammation and lack of neurokinin receptor expression in primary afferent sensory neurons
15. A comparison of the anatomical distribution of substance P and substance P receptors in the rat central nervous system
16. Localization of beta pre-protachykinin mRNA in nodose ganglion
17. Demonstration of rat preprotachykinin A mRNA in the rat trigeminal ganglion by in situ hybridization histochemistry
18. Tachykinin and calcitonin gene-related peptide immunoreactivities and mRNAs in the mammalian enteric nervous system and sensory ganglia
19. Coexistence of calcitonin gene-related peptide and substance P-like peptide in single cells of the trigeminal ganglion of the rat: Immunohistochemical analysis
20. Pathway-specific patterns of the co-existence of substance P, calcitonin gene-related peptide, cholecystokinin and dynorphin in neurons of the dorsal root ganglia of the guinea-pig
21. Cellular sites of expression of the neurokinin-1 receptor in the rat gastrointestinal tract
22. Messenger plasticity in primary sensory neurons following axotomy and its functional implications
23. A noxious stimulus induces the preprotachykinin-A gene expression in the rat dorsal root ganglion: A quantitative study using in situ hybridization histochemistry
24. Modifications of serotonin-, substance P- and calcitonin gene-related peptide-like immunoreactivities in the dorsal horn of the spinal cord of arthritic rats: A quantitative immunocytochemical study
25. Release of immunoreactive substance P in the spinal cord during development of acute arthritis in the knee joint of the cat: A study with antibody microprobes
26. Cycloheximide-sensitive synthesis of substance P by isolated dorsal root ganglia
27. Synthesis, and central and peripheral axonal transport of substance P in a dorsal root ganglion-nerve preparation in vitro
28. Ultrastructural studies on calcitonin gene-related peptide-, tachykinins- and somatostatin-immunoreactive neurones in rat dorsal root ganglia: Evidence for the colocalization of different peptides in single secretory granules
29. Peptide coexistence in axon terminals within the superficial dorsal horn of the rat spinal cord
30. Axonal transport of substance P in the vagus and sciatic nerves of the guinea pig
31. Regional distribution of substance P in the spinal cord and nerve roots of the cat and the effect of dorsal root section
32. Substance P in the vagus nerve. Immunochemical and immunohistochemical evidence for axoplasmic transport
33. Substance P in rat CNS and duodenum during development
34. The origin, distribution and synaptic relationships of substance P axons in rat spinal cord
35. Electron microscope immunohistochemical localization of substance P in the central nervous system of the rat
36. Ultrastructural localization of substance P in neurons of rat spinal cord
37. Substance P neurons project from the ventral medulla to the intermediolateral cell column and ventral horn in the rat
38. Immunohistochemical study of neuropeptides in vagal and glossopharyngeal afferent neurons in the rat
39. After axotomy, substance P and vasoactive intestinal peptide expression occurs in pilomotor neurons in the rat superior cervical ganglion
40. On the occurrence of substance P-containing fibers in sympathetic ganglia: Immunohistochemical evidence
41. Neurokinin-1 receptor localisation in guinea pig autonomic ganglia
42. Effects of substance P on neurones of the inferior mesenteric ganglia of the guinea-pig
43. The metabolism of neuropeptides. The hydrolysis of peptides, including enkephalins, tachykinins and their analogues, by endopeptidase-24.11
44. The immunocytochemical localisation of 'substance-P-degrading enzyme' within the rat spinal cord
45. Cleavage of peptide bonds by angiotensin I converting enzyme
46. Liver dipeptidyl aminopeptidase IV hydrolyzes substance P
47. Cleavage of substance P to an N-terminal tetrapeptide and a C-terminal heptapeptide by a post-proline cleaving enzyme from bovine brain
48. Substrate specificity of cerebral cathepsin D and high-Mr aspartic endopeptidase
49. Rabbit procathepsin E and cathepsin E. Nucleotide sequence of cDNA, hydrolytic specificity for biologically active peptides and gene expression during development
50. Neutral endopeptidase modulates neurogenic inflammation
51. Isolation of two differentially glycosylated forms of peptidyl-dipeptidase A (angiotensin converting enzyme) from pig brain: A re-evaluation of their role in neuropeptide metabolism
52. Phosphoramidon potentiates mammalian tachykinin-induced biting, licking and scratching behaviour in mice
53. Regulation of airway neurogenic inflammation by neutral endopeptidase
54. Differential processing of substance P and neurokinin A by plasma dipeptidyl(amino)peptidase IV, aminopeptidase M and angiotensin converting enzyme
55. The control of microvascular permeability and blood pressure by neutral endopeptidase
56. Acute ACE inhibition causes plasma extravasation in mice that is mediated by bradykinin and substance P
57. Molecular aspects of the tachykinin receptors
58. Mammalian tachykinin receptors
59. The dual nature of the tachykinin NK1 receptor
60. Functional characterization by heterologous expression of a novel cloned tachykinin peptide receptor
61. 7]neurokinin B, and is responsive to tachykinin peptide agonists
62. Tachykinin-induced activation of non-specific cation conductance via NK3 neurokinin receptors in guinea-pig intracardiac neurones
63. Human substance P receptor (NK-1): Organization of the gene, chromosome localization, and functional expression of cDNA clones
64. The extracellular domain of substance P (NK1) receptor comprises part of the ligand binding site
65. Molecular basis for the species selectivity of the substance P antagonist CP-96345
66. Molecular characterization of a functional cDNA encoding the rat substance P receptor
67. Interaction of substance P with the second and seventh transmembrane domains of the neurokinin-1 receptor
68. Human substance P receptor expressed in Chinese hamster ovary cells directly activates G(alpha q/11), G(alpha s), G(alpha o)
69. Multiple mechanisms of arachidonic acid release in Chinese hamster ovary cells transfected with cDNA of substance P receptor
70. Ligand binding kinetics of substance P and neurokinin A receptors stably expressed in Chinese hamster ovary cells and evidence for differential stimulation of inositol 1,4,5-trisphosphate and cyclic AMP second messenger responses
71. Tachykinin peptides affect differently the second messenger pathways after binding to CHO-expressed human NK-1 receptors
72. Pharmacological characterization and autoradiographic localization of substance P receptors in guinea pig brain
73. Substance P release in the dorsal horn assessed by receptor internalization: NMDA receptors counteract a tonic inhibition by GABA(B) receptors
74. Effects of substance P on adult rat sensory ganglion neurones in vitro
75. Small sensory neurons in the rat dorsal root ganglia express functional NK-1 tachykinin receptor
76. Expression of tachykinin NK1 receptor mRNA in dorsal root ganglia of the mouse
77. Localization and activation of substance P receptors in unmyelinated axons of rat glabrous skin
78. Tachykinin NK1 receptor subtypes in the rat urinary bladder
79. The 'septide-sensitive' tachykinin receptor: Still an enigma
80. The expanding family of guanylyl cyclases
81. Differential activation of the epithelial and smooth muscle NK1 receptors by synthetic tachykinin agonists in guinea-pig trachea
82. Peptide autoreceptors: Does an autoreceptor for substance P exist?
83. Tachykinin autoreceptors in the gut
84. Dual effects of substance P on the excitability of single cutaneous primary afferent C- and A-fibers in the cat spinal cord
85. Substance P depolarizes nerve terminals in an autonomic ganglion
86. Inflammation-induced changes in primary afferent-evoked release of substance P within trigeminal ganglia in vivo
87. Cross-excitation in dorsal root ganglia of nerve-injured and intact rats
88. Effect of the tachykinin NK1 receptor antagonists, RP 67580 and SR 140333, on electrically-evoked substance P release from rat spinal cord
89. Functional changes in dorsal root ganglion cells after chronic nerve constriction in the rat
90. Synthesis and biological properties of enzyme-resistant analogues of substance P
91. A model for evaluation of postural hypotension induced by drugs in conscious restrained normotensive rats
92. Selective agonists for substance P and neurokinin receptors
93. Binding sites for [3H][Sar9, Met(O2)11]substance P in rat brain and guinea pig ileum
94. Receptors mediating tachykinin-evoked depolarisations of neurons in the neonatal rat spinal cord
95. Characterization of tachykinin receptors in the uterus of the oestrogen-primed rat
96. Septide: An agonist for the NK1 receptor acting at a site distinct from substance P
97. GR 73,632 and [Glu(OBzl)11]substance P are selective agonists for the septide-sensitive tachykinin NK1 receptor in the rat urinary bladder
98. On peptide synthesis. C-terminal partial sequences of eledoisins and eledoisin analogs
99. Nerves containing substance P, vasoactive intestinal polypeptide, enkephalin or somatostatin in the guinea-pig taenia coli. Distribution, ultrastructure and possible functions
100. Pharmacological characterization of four related substance P antagonists
101. A substance P antagonist, [d-Pro2, d-Trp7,9]SP, inhibits inflammatory responses in the rabbit eye
102. Peptides and histamine release from rat peritoneal mast cells
103. Characterization of CP-122,721; a nonpeptide antagonist of the neurokinin NK1 receptor
104. Studies on neurokinin antagonists. 2. Design and structure-activity relationships of novel tripeptide substance P antagonists, N alpha-[N alpha-(N alpha-acetyl-l-threonyl)-N1-formyl-d-tryptophyl]-N-methyl-N-(phenylmethyl)- l-phenylalaninamide and its related compounds
105. Studies on neurokinin antagonists. 4. Synthesis and structure-activity relationships of novel dipeptide substance P antagonists: N2-[(4R)-4-hydroxy-1-[(1-methyl-1H-indol-3-yl)carbonyl]-l-prolyl]-N-methyl- N-(phenylmethyl)-3-(2-naphthyl)-l-alaninamide and its related compounds
106. Effect of CP-96,345, a nonpeptide substance P receptor antagonist, on salivation in rats
107. Pharmacology of CP-99,994; a nonpeptide antagonist of the tachykinin neurokinin-1 receptor
108. The discovery of (2S,3S)-cis-2-(diphenylmethyl)-N-[(2-methoxyphenyl)methyl]-1-azabicyclo- [2.2.2]-octan-3-amine as a novel, nonpeptide substance P antagonisst
109. Pharmacological properties of a potent and selective nonpeptide substance P antagonist
110. In vitro and in vivo biological activities of SR140333, a novel potent non-peptide tachykinin NK1 receptor antagonist
111. Selective neurokinin-1 receptor antagonists are anti-hyperalgesic in a model of neuropathic pain in the guinea-pig
112. Anxiolytic action of a neurokinin1 receptor antagonist in the social interaction test
113. SR140333, a substance P receptor antagonist, influences morphological and motor changes in rat experimental colitis
114. Neurokinin-1 receptor antagonist SR140333: A novel type of drug to treat cerebral ischemia
115. GR205171: A novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity
116. The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets
117. Involvement of substance P in the anti-inflammatory effects of the peripherally selective kappa-opioid asimadoline and the NK1 antagonist GR205171
118. Distinct mechanism for antidepressant activity by blockade of central substance P receptors
119. The substance P receptor antagonist CP-99,994 reduces acute postoperative pain
120. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist
121. Vanilloid (Capsaicin) receptors and mechanisms
122. The capsaicin receptor: A heat-activated ion channel in the pain pathway
123. Protons: Small stimulants of capsaicin-sensitive sensory nerves
124. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide
125. Effects of capsaicin on the development of gastric mucosal damage by different necrotizing agents and of gastric cytoprotection by PGI2 atropine and cimetidine on rats
126. Sensory neuropeptide release by bradykinin: Mechanisms and pathophysiological implications
127. Local effector functions of capsaicin-sensitive sensory nerve endings: Involvement of tachykinins, calcitonin gene-related peptide and other neuropeptides
128. The pharmacology of the efferent function of sensory nerves
129. Vascular protein linkage in various tissue induced by substance P, capsaicin, bradykinin, serotonin, histamine and by antigen challenge
130. Low pH-induced release of calcitonin gene-related peptide from capsaicin-sensitive sensory nerves: Mechanism of action and biological response
131. A new NK1 receptor antagonist (CP-99,994) prevents the increase in tracheal vascular permeability produced by hypertonic saline
132. Tachykinin and kinin receptor antagonists: Therapeutic perspectives in allergic airway disease
133. The role of tachykinin receptor antagonists in the prevention of bronchial hyperresponsiveness, airway inflammation and cough
134. Intradermal injection of capsaicin in humans produces degeneration and subsequent reinnervation of epidermal nerve fibers: Correlation with sensory function
135. Immunohistochemical detection of human skin nerve fibers
136. Characterization of [3H]substance P binding sites in human skin
137. Neurogenic vasodilatation and plasma leakage in the skin
138. Neurogenic inflammation in skin and airways
139. Structure-activity relationships for some substance P-related peptides that cause wheal and flare reactions in human skin
140. Histamine release and local responses of rat and human skin to substance P and other mammalian tachykinins
141. Sensory neuropeptide effects in human skin
142. The use of cutaneous microdialysis to measure substance P-induced histamine release in intact human skin in vivo
143. Endogenous opioids and ruthenium red inhibit the flare reaction in the pig skin by different mechanisms
144. Histamine is released from skin by substance P but does not act as the final vasodilator in the axon reflex
145. No release of histamine and substance P in capsaicin-induced neurogenic inflammation in intact human skin in vivo: A microdialysis study
146. Plasma extravasation and neuropeptide release in human skin as measured by intradermal microdialysis
147. Inhibitory effects of tachykinin receptor antagonists on thermally induced inflammatory reactions in a rat model
148. Effect of a neurokinin-1 (NK1) receptor antagonist on oedema formation induced by tachykinins, carrageenin and an allergic response in guinea-pig skin
149. The formalin test: An evaluation of the method
150. Regulation of neurokinin-1 receptor expression by GABA(B) receptor agonists
151. The neurokinin-1 receptor antagonist LY306,740 blocks nociception-induced increases in dorsal horn neurokinin-1 receptor gene expression
152. Concentration of substance P-like immunoreactivity (SPLI) in tissues of dog, rat and mouse
153. Peptidergic innervation (substance P) in the human heart
154. Enkephalin-, VIP- and substance P-like immunoreactivity in the carotid body
155. Tachykinins and calcitonin gene-related peptide (CGRP) as co- transmitters released from peripheral endings of sensory nerves
156. N omega-nitro-l-arginine blocks the second phase but not the first phase of the endothelium-dependent relaxations induced by substance P in isolated rings of pig carotid artery
157. Calcitonin gene-related peptide acts as a novel vasodilator neurotransmitter in mesenteric resistance vessels of the rat
158. Direct observation of substance P-induced internalization of neurokinin 1 (NK1) receptors at sites of inflammation
159. Cigarette smoke-induced airway oedema due to activation of capsaicin-sensitive vagal afferents and substance P release
160. Tachykinins, via NK1 receptor activation, play a relevant role in plasma protein extravasation evoked by allergen challenge in the airways of sensitized guinea-pigs
161. Involvement of neurogenic inflammation in antigen-induced bronchoconstriction in guinea pigs
162. Clinical and inflammatory responses to exogenous tachykinins in allergic rhinitis
163. Substance P: Localization, concentration and release in cerebral arteries, choroid plexus and dura mater
164. Effects of neuropeptide Y, calcitonin gene-related peptide, substance P, and capsaicin on cerebral arteries in man and animals
165. Inhibition of neurogenic inflammation in the meninges by a non-peptide NK1 receptor antagonist, RP 67580
166. Investigation of the role of tachykinin NK1, NK2 receptors and CGRP receptors in neurogenic plasma protein extravasation in dura mater
167. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine
168. Substance P immunoreactive nerves in the rodent cornea
169. Substance P-immunoreactive nerve fibres in the anterior segment of the rabbit eye. Distribution and possible physiological significance
170. Responses to antidromic trigeminal nerve stimulation, substance P, NKA, CGRP and capsaicin in the rat eye
171. Effects of neurokinin A, substance P and electrical stimulation on the rabbit iris sphincter muscle
172. Neurokinin receptors in the rabbit iris sphincter characterised by novel agonist ligands
173. Involvement of tachykinins in plasma extravasation induced by bradykinin and low pH medium in the guinea-pig conjunctiva
174. Evidence that tachykinins relax the guinea-pig trachea via nitric oxide release and by stimulation of a septide-insensitive NK1 receptor
175. Ruthenium red, but not capsazepine reduces plasma extravasation by cigarette smoke in rat airways
176. Characterisation of the neurokinin receptors mediating contraction of isolated tracheal preparations from a variety of species
177. Evidence for functional tachykinin NK1 receptors on human isolated small bronchi
178. NK1 receptor causes contraction and inositol phosphate increase in medium size human bronchi
179. Effects of tachykinins on mucus secretion in human bronchi in vitro
180. Substance P and capsaicin release prostaglandin E2 from rat intrapulmonary bronchi
181. Induction of tachykinin gene and peptide expression in guinea pig nodose primary afferent neurons by allergic airway inflammation
182. Sensory nerve activation in airway microvascular permeability in guinea-pig late allergic response
183. Involvement of tachykinin NK1 receptor in the development of allergen-induced airway hyperreactivity and airway inflammation in conscious, unrestrained guinea pigs
184. Neurogenic amplification of immune complex inflammation
185. Substance P immunoreactive nerves in airways from asthmatics and nonasthmatics
186. Neuropeptide content of lungs from asthmatic and nonasthmatic patients
187. Modulation of sensory nerve function in the airways
188. Elevated substance P content in induced sputum from patients with asthma and patients with chronic bronchitis
189. Substance P and beta-endorphin-like immunoreactivity in lavage fluids of subjects with and without allergic asthma
190. Mucosal nerves in endobronchial biopsies in asthma and non-asthma
191. Increased tachykinin receptor gene expression in asthmatic lung and its modulation by steroids
192. The distribution of neurokinin-1 and neurokinin-2 receptors in human central airways
193. Roles of neutral endopeptidase in airways
194. Neutral endopeptidase activity and airway hyperresponsiveness to neurokinin A in asthmatic subjects in vivo
195. Neuropeptides in the respiratory tract. Part I
196. Neuropeptides in the respiratory tract. Part II
197. Neutral endopeptidase and neurogenic inflammation in rats with respiratory infections
198. Toluene diisocyanate increases airway responsiveness to substance P and decreases airway neutral endopeptidase
199. Chemical coding of enteric neurons
200. Release of substance P from the enteric nervous system: Direct quantitation and characterization
201. Tachykinins in the gut. Part II. Roles in neural excitation, secretion and inflammation
202. A study of the concentrations of substance P and neurotensin in the gastrointestinal tract of various mammals
203. Intramural distribution of regulatory peptides in the human stomach and duodenum
204. Intramural distribution of immunoreactive vasoactive intestinal polypeptide (VIP), substance P, somatostatin and mammalian bombesin in the oesophago-gastro-pyloric region of the human gut
205. Tissue localization and relative distribution of regulatory peptides in separated layers from the human bowel
206. Tachykinin NK1 and NK2 receptors mediate atropine-resistant ileal circular muscle contractions evoked by capsaicin
207. The inhibitory modulation of guinea-pig intestinal peristalsis caused by capsaicin involves calcitonin gene-related peptide and nitric oxide
208. Synergistic role of muscarinic acetylcholine and tachykinin NK-2 receptors in intestinal peristalsis
209. Tachykinin NK1 and NK2 receptor antagonists and atropine-resistant ascending excitatory reflex to the circular muscle of the guinea-pig ileum
210. Comparison of tachykinin NK1 and NK2 receptors in the circular muscle of the guinea-pig ileum and proximal colon
211. Investigations of nerve populations influencing ion transport that can be stimulated electrically, by serotonin and by a nicotinic agonist
212. Tachykinin-induced anion secretion in guinea pig distal colon: Role of neural and inflammatory mediators
213. Increased substance P receptor expression by blood vessels and lymphoid aggregates in Clostridium difficile-induced pseudomembranous colitis
214. Receptor binding sites for substance P, but not substance K or neuromedin K, are expressed in high concentrations by arterioles, venules, and lymph nodules in surgical specimens obtained from patients with ulcerative colitis and Crohn disease
215. Pathophysiology of pancreatitis. Role of cytokines and other mediators of inflammation
216. Substance P mediates inflammatory oedema in acute pancreatitis via activation of the neurokinin-1 receptor in rats and mice
217. Substance P receptor expression in intestinal epithelium in Clostridium difficile toxin A enteritis in rats
218. Neurokinin-1 (NK-1) receptor is required in Clostridium difficile-induced enteritis
219. Substance P activation of enteric neurons in response to intraluminal Clostridium difficile toxin A in the rat ileum
220. Downregulation of neutral endopeptidase (EC 3.4.24.11) in the inflamed rat intestine
221. Substance P and bradykinin stimulate plasma extravasation in the mouse gastrointestinal tract and pancreas
222. Plasma extravasation induced by neurokinins in conscious rats: Receptor characterization with agonists and antagonists
223. Autoradiographic localization of tachykinin and calcitonin gene-related peptide receptors in adult urinary bladder
224. Visceromotor responses to calcitonin gene-related peptide (CGRP) in the rat lower urinary tract: Evidence for a transmitter role in the capsaicin-sensitive nerves of the ureter
225. Characterisation of NK receptors in guinea-pig urinary bladder smooth muscle: Use of selective antagonists
226. Neurokinin receptors in the rat lower urinary tract
227. In vivo evidence for tachykininergic transmission using a new NK-2 receptor-selective antagonist, MEN 10376
228. The contractile effect of tachykinins on human prostatic urethra: Involvement of NK-2 receptors
229. Effects of the substance P receptor antagonist CP-96,345 on renal sensory receptor activation
230. Co-localization of tachykinins and calcitonin gene-related peptide in capsaicin-sensitive afferents in relation to motility effects on the human ureter in vitro
231. Tachykinin-like immunoreactivity in the mammalian urinary bladder: Correlation with the functions of the capsaicin-sensitive sensory nerves
232. Topical versus systemic capsaicin desensitization: Specific and unspecific effects as indicated by modification or reflex micturition in rats
233. The contribution of sensory nerves to xylene-induced cystitis in rats
234. Increased expression of substance P receptor-encoding mRNA in bladder biopsies from patients with interstitial cystitis
235. High affinity binding sites for [3H]substance P in urinary bladders of cats with interstitial cystitis
236. Expression of neuropeptides and nitric oxide synthase in neurones innervating the inflamed rat urinary bladder
237. Effects of neuropeptides on neutrophil migration through noncellular and endothelial barriers
238. Tachykinins: Effects on motility and metabolism of rat polymorphonuclear leucocytes
239. Tachykinins stimulate lyso-PAF:acetyl-CoA acetyltransferase activity in neutrophils
240. Activation of human neutrophils by tachykinins: Effect on formyl-methionyl-leucyl-phenylalanine- and platelet-activating factor-stimulated superoxide anion production and antibody-dependent cell-mediated cytotoxicity
241. Effect of substance P on superoxide anion and IL-8 production by human PMNL
242. Immunoregulatory effect of substance P in human eosinophil migratory function
243. Priming of normal human neutrophils by tachykinins: Tuftsin-like inhibition of in vitro chemotaxis stimulated by formylpeptide or interleukin-8
244. Intracellular signaling pathway of substance P-induced superoxide production in human neutrophil
245. Stereospecific receptors for substance P on cultured human IM-9 lymphoblasts
246. Substance P recognition by a subset of human T lymphocytes
247. Substance P receptors and signal transduction in leukocytes
248. Substance P: Binding properties and studies on cellular responses in guinea pig macrophages
249. Increased susceptibility of mice to Salmonella infection following in vivo treatment with the substance P antagonist, spantide II
250. Nanomolar concentrations of neuropeptides induce histamine release from peritoneal mast cells of a substrain of Wistar rats
251. The in vivo effect of tachykinins on airway mast cells of the rat
252. Neurogenic inflammation, vascular permeability, and mast cells. II. Additional evidence indicating that mast cells are not involved in neurogenic inflammation